Macrolide immunosuppressants.

U Mrowietz

PubMed · 10417434

Macrolide immunosuppressants.

Abstract

Macrolide immunosuppressants are a new class of compounds sharing a macrolide-like structure and potent immunosuppressive activity in vitro and in vivo. Tacrolimus, the best known substance of this group, is registered in many countries for the prevention of transplant rejection. Numerous new substances of this group are in the pipelines of the pharmaceutical industries. Macrolide immunosuppressants are also effective in dermatological disorders. Due to their chemical structure these compounds can be used for topical treatment. Clinical studies have already shown highly effective topical therapy of atopic dermatitis with tacrolimus and the ascomycin derivative SDZ ASM 981, another macrolide immunosuppressant. In this article the pharmacological aspects of macrolide immunosuppressants, their supposed mechanisms of action, pre-clinical and clinical experience are reviewed.

Explore related subjects

Cyclosporine Dermatologic Agents Humans Immunosuppressive Agents Macrolides Skin Diseases Tacrolimus Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

U Mrowietz. Macrolide immunosuppressants.. https://pubmed.ncbi.nlm.nih.gov/10417434/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome.

We report a case of idiopathic inflammatory myopathy accompanied with the presence of anti-Jo1 antibodies and complicated by diffuse parenchymal lung disease (antisynthetase syndrome). Efficacy of different therapeutic agents, including corticosteroids, cyclophosphamide and cyclosporin A, is described. We present beneficial effect of cyclosporin A and corticosteroids regimen, and confirm no benefits of plasmapheresis. An interesting association of the disease onset with toxoplasmosis infection is discussed and difficulties regarding diagnosis of cardiac involvement are addressed. We also review other case reports of this rare disorder of poor prognosis.

Cyclosporine↗

PubMed2007

Update on gingival overgrowth by cyclosporine A in renal transplants.

Severe gingival overgrowth is one of the most frequent side effects in renal transplant patients associated with assumption of cyclosporine A. Several associations with age, sex, dosage, duration of therapy or interval since transplantation have been hypothesized. The introduction of alternative immunosuppressant drugs have been suggested to permit better long-term transplant outcomes and a decrease in incidence of gingival overgrowth. The aim of the present paper is to summarize current knowledge regarding aetiology, pathogenesis and management of gingival overgrowth induced by Cyclosporine A.

Cyclosporine↗

PubMed2007

Severe psoriasis treated with a new macrolide: everolimus.

Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.

Cyclosporine↗